March 1989
Volume 30, Issue 3
Free
Articles  |   March 1989
The role of inflammation in CW Nd:YAG contact transscleral photocoagulation and cryopexy.
Author Affiliations
  • H D Schubert
    Retina Service, Wills Eye Hospital, Philadelphia, PA 19107.
  • J L Federman
    Retina Service, Wills Eye Hospital, Philadelphia, PA 19107.
Investigative Ophthalmology & Visual Science March 1989, Vol.30, 543-549. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H D Schubert, J L Federman; The role of inflammation in CW Nd:YAG contact transscleral photocoagulation and cryopexy.. Invest. Ophthalmol. Vis. Sci. 1989;30(3):543-549.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

Cyclodestructive modalities in humans have been shown to be effective when applied 3.5 mm or more posterior to the limbus. Therefore, CW Nd:YAG contact transscleral laser and cryopexy were applied 6 mm posterior to the limbus of pigmented rabbits. The intraocular pressure (IOP), flare, iritis, cells and conjunctival hyperemia were monitored clinically up to 3 weeks. The pressure lowering effect was -7.5 +/- 7.7 mm Hg for laser retinopexy and -14.2 +/- 6.0 mm Hg for retinocryopexy at 3 weeks and was comparable to application of the same modalities directly over the ciliary body. Similarly, induction of intraocular inflammation by injecting 10 micrograms of endotoxin intravitreally lowered IOP significantly. These findings suggest that hypotension may not be directly due to cyclodestruction but may be related to the ocular irritative response and extent of neuroepithelial defect, irrespective of its distance from the limbus.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×